As part of her continuing conversation with PharmExec, Trialynx CEO Angela Schwab goes into detail the importance of understanding a site’s abilities during the development stage of a trial.
Angela Schwab
Advertisement
Articles by Angela Schwab
Angela Schwab, founder and CEO of Trialynx, discusses the importance of designing trials around patients and how doing so doesn’t have to come at the cost of generating good data.
In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and solutions for high failure rates in clinical trials.
Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.
Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s important for companies to demonstrate the true value of their AI-based products.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist
2
Boehringer Ingelheim Enters $1.26 Billion Collaboration and License Agreement with Simcere Pharmaceuticals to Develop Pre-Clinical Bispecific Antibody
3
Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist
4
Bringing a Breakthrough Rare Disease Product to Patients: Q&A with Helen Sabzevari
5